assessed for 28 oncogenes using Next Genuine Sequencing on the Illumina SMP2 panel. Results: 116 patients were consented from 6/10/14-1/10/15 referred from 12 oncologists. The data on patient/sample flow is shown in Fig  1. Median survival was 161 days from consent. The 1st sample was sent to Cardiff on 28/1/15 as the Illumina panel was undergoing final validation. 50 samples have been sent; 11 had insufficient DNA; these samples had lower cell number (but with no impact of necrosis/tumour proportion); The most commonly altered gene was K-Ras (13 of 22 adenocarcinomas). Only 2 patients with results from >25 of the 28 genes had no tier 1 or 2 ie potentially treatable molecular abnormalities. The median time from consent to result was 109 days (range 45-250) with delays occurring throughout the pathway.
Conclusion:
Patients and oncologists are keen to be involved in molecular profiling; but patients need to be consented early to allow results to guide therapy. Prioritisation of samples is key. Not all samples are suitable for analysis due to small cell number or low tumour proportion. Molecular analysis may require extra resource in pathology, if it is to become standard of care. The first 4 patients to start treatment on MATRIX were enrolled from 27/8/15 in Newcastle. Disclosure: All authors have declared no conflicts of interest. Treatment-emergent AEs in ≥30% of total patients (N=137), generally grades 1/2, included nausea (52%), fatigue (42%), diarrhea (40%), headache (33%), and cough (32%); serious AEs in ≥2% of all patients, regardless of attribution, included dyspnea (7%), pneumonia (6%), hypoxia (5%), pulmonary embolism (3%), and pyrexia (2%).
Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC

Conclusion:
Brigatinib had antitumor activity in ALK+ NSCLC patients with (71% ORR; median PFS, 13.4 months) or without (100% ORR) prior crizotinib, including patients with brain metastases (53% ORR, measurable brain lesions). A pivotal, randomized, phase 2 trial of brigatinib in patients with crizotinib-resistant ALK+ NSCLC is on-
